Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2012
March 2012, Vol 3, No 2
March 2012, Vol 3, No 2
Many Patients with mRCC Ineligible for Clinical Trials
By
Wayne Kuznar
Genitourinary Cancers Symposium
March 2012, Vol 3, No 2
San Francisco, CA—A large number of patients with metastatic renal-cell carcinoma (mRCC) are ineligible for clinical trials and their clinical outcomes are inferior to those of patients who are trial eligible, according to a study presented at the 2012 Genitouri nary Cancers Symposium.
Read Article
Nonpharmacologic Strategies Have Mixed Results in Prostate Cancer Prevention
By
Phoebe Starr
Genitourinary Cancers Symposium
March 2012, Vol 3, No 2
San Francisco, CA—Nonpharmacologic strategies for prevention of cancer are potentially attractive and costeffective, but success stories are few.
Read Article
For Metastatic Breast Cancer, Nab-Paclitaxel Requires Less Growth Factor Support
By
Caroline Helwick
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
March 2012, Vol 3, No 2
San Antonio, TX—In a retrospective utilization and cost analysis, nab-paclitaxel (Abraxane) therapy was associated with substantially lower total use of prophylactic colony-stimulating factor (CSF) than docetaxel (Taxotere) and paclitaxel (Taxol) in the treatment of breast cancer.
Read Article
Oncotype DX Assay Cost-Effective for Patients with ER-Positive Breast Cancer
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
March 2012, Vol 3, No 2
San Antonio, TX—Assessing all eligible patients with breast cancer for recurrence risk with the 21-gene Onco
type
DX assay at diagnosis could save $330.8 million annually by avoiding ineffective chemotherapy, according to data presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium.
Read Article
New Data Suggest Oncotype DX Unnecessary in Some Cases of Low-Grade Cancer
By
Rosemary Frei, MSc
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
March 2012, Vol 3, No 2
Grapevine, TX—A New Jersey research team is making the case for relying less on the Onco
type
DX test for breast-cancer prognosis and instead focusing on conventional pathological analyses.
Read Article
Dose-Dense Chemotherapy plus Growth Factors in Elderly ER-Positive Patients Unnecessary, Costly
By
Caroline Helwick
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
March 2012, Vol 3, No 2
San Antonio, TX—Women with estrogen receptor (ER)-positive breast cancer are unlikely to benefit from dosedense chemotherapy, but many are receiving this type of treatment, which involves the use of colonystimulating factors (CSFs), that is, growth factors. Limiting the use of these therapies in a population that is unlikely to benefit from it, would save nearly $40 million annually, suggests a study presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium.
Read Article
For Pancreatic Cancer, Neoadjuvant Chemoradiation Cost-Effective Compared with Surgery First
By
Caroline Helwick
Gasterol Intestinal Symposium
March 2012, Vol 3, No 2
San Francisco, CA—For resectable pancreatic cancer, administering chemo - therapy and radiation before surgery results in better outcomes and lower costs than performing surgery first, reported researchers from M.D. Anderson Cancer Center, Houston.
Read Article
Oncotype DX Assay Changes 29% of Treatment Decisions in Patients with Stage II Colon Cancer
Gasterol Intestinal Symposium
March 2012, Vol 3, No 2
San Francisco, CA—Results obtained on the Onco
type
DX Colon Cancer Assay led to changes in treatment decisions 29% of the time for patients with stage II colon cancer, according to a survey of community oncologists reported at the 2012 Gastrointestinal Cancers Symposium.
Read Article
Economic Burden of Febrile Neutropenia in NHL Exceeds $11,000 per Episode
By
Caroline Helwick
ASH Highlights
,
ASH 2011 Annual Meeting
March 2012, Vol 3, No 2
San Diego, CA—Among patients with non-Hodgkin lymphoma (NHL), costs related to febrile neutropenia (FN) treated with hospitalization exceed $11,000 per episode, researchers reported at ASH 2011.
Read Article
Long-Term Survivors of Hematopoietic Stem-Cell Transplant Pose Significant Burden to Healthcare System
By
Phoebe Starr
ASH Highlights
,
ASH 2011 Annual Meeting
March 2012, Vol 3, No 2
San Diego, CA—Survivors of hematopoietic cell transplant (HCT) have substantial medical illnesses and psychological symptoms ≥10 years after the procedure, representing a substantial burden to our healthcare system.
Read Article
Page 3 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma